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We studied 12450 cases of invasive melanoma diagnosed in Scotland in 1979–2003, by thickness, pathological type, and body site at
ages under 40, 40–59, and 60 years and over. Melanoma incidence trebled in males from 3.57 to 10.93/10
5 per year, and increased
2.3-fold in females from 5.60 to 12.96/10
5 per year. The rate of increase fell in each successive 5-year period. The greatest increase
was in males aged 60 years and over at diagnosis. Significant incidence increases were seen in melanomas o1mm in all three age
groups, but those 44mm only increased significantly at ages 60 years and over. All histological types increased significantly at ages 60
years and over, and in this age group the greatest increase was seen on the head and neck. Five-year disease-free survival improved
steadily. Survival figures for 1994–1998 ranged from 93.6% for males and 95.8% for females with tumours o1mm, to 52.4 and
48.3%, respectively, for those with tumours 44mm. Over the 25 years, melanoma mortality doubled in males from 1.1 to 2.4/10
5
per year, but was unchanged in females at 1.5/10
5 per year. Public education on melanoma is required both for primary prevention
and earlier diagnosis, particularly for older males.
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Cutaneous melanoma is a cause of concern for those involved in
cancer control in Europe (de Vries et al, 2003; Hemminki et al,
2003; de Vries and Coebergh, 2004), North America (Jemal et al,
2001; Swetter et al, 2005), and Australasia (Martin and Robinson,
2004; Baade and Coory, 2005; Coory et al, 2006). Data from all
three continents show a continuing rise in incidence, although in
some countries incidence figures may be stabilising in younger
females. Mortality shows a slower rise than incidence and even a
falling trend in some countries (Bosetti et al, 2004; Schaffer et al,
2005). Since 1979, The Scottish Melanoma Group has kept detailed
population-based records of all new cases of invasive melanoma
diagnosed in Scotland in both the National Health Service and the
private sector. These data differ from that gathered by the Scottish
Cancer Registry by inclusion of tumour thickness. At a time when
there is concern over the rising incidence of melanoma, termed
‘the melanoma epidemic’ in the US (Schaffer et al, 2005), change in
the incidence by tumour thickness is a useful indicator of probable
future morbidity and mortality resulting from patients with thicker
tumours who are likely to progress to AJCC stage 3 and 4 disease.
In this paper, we present a 25-year report of the changing
melanoma incidence and mortality in Scotland to complement
previous reports (Mackie et al, 1985, 1992, 1997, 2002), together
with relative changes in incidence by sex, age group, tumour
thickness, and histological type. Such data may guide future public
health messages aimed at prevention and earlier diagnosis.
METHODS
Pathologists in Scotland (latitude 55–591 North, population 5.1
million) supply information on all newly diagnosed invasive
cutaneous melanomas (Clark level 2 or deeper), including tumour
thickness, histological type, body site, and other details. Cases
recorded in this way by the Scottish Melanoma Group are cross-
checked with the Scottish Cancer Registry to ensure completeness
of registration. All cases pathologically ratified by both sources are
included in the analysis. Information on treatment and follow-up
is obtained from the relevant clinician at regular intervals. Causes
of death are checked with the death certificates, and rarely, when
cases are lost to follow-up.
Cases were considered in three age groups: under 40, 40–59, and
60 years and over at diagnosis, by histological type as superficial
spreading melanoma, nodular melanoma, lentigo maligna mela-
noma, and acral melanoma. Finally, four main body sites of head
and neck, trunk, upper limb, and lower limb were considered.
To ensure an adequate number of cases for analysis when
further subdivided by tumour thickness, histological type, and
body site, we have reported results in 5-year periods: 1979–1983,
1984–1988, 1989–1993, 1994–1998, and 1999–2003. Incidence
rates for the whole group were calculated and also for the three age
groupings at diagnosis, all age-standardised to the European
population (EASR). Changes in overall incidence rates between the
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and by tumour thickness, pathological subtype, and body site. The
number of cases was assumed to follow a Poisson distribution and
the P-value for the ratio of the two rates was based on a log-linear
model using Wald’s method (Price and Bonnet, 2000). Mean
annual percentage changes in incidence within each 5-year period
were calculated and compared with each successive cohort for all
patients and by age group.
The association between 5-year survival and each 5-year period
was assessed using w
2 tests for trend.
RESULTS
Table 1 gives details for the five quinquennia, with a total of 12450
cases, 4810 males and 7640 females. Between 1979 and 2003,
incidence trebled in males from 3.57 to 10.93/10
5 per year, and rose
2.3-fold in females from 5.6 to 12.96/10
5 per year (each Po0.001).
The female:male ratio is 1.6:1 for the whole time period, falling
from 2.1:1 in 1979 to 1.3:1 in 2003. The annual percentage
increase in incidence declined from a mean of 11.3% for both sexes
in the first 5-year period to a mean of 2.95 and 2.1% for males and
females, respectively, in 1999–2003.
Table 2 divides the cases further by quinquennium, by sex, and
into three age groups at diagnosis under 40, 40–59, and 60 years
and over. Over the 25-year period, a steady upward trend in
incidence is seen in both sexes and all age groups, which is most
marked in those aged 60 years and over where in 1998–2003 the
male incidence at 34.17 exceeds that of the females at 29.62/10
5 per
year. The mean annual percentage change in incidence in each
5-year group by age and sex shows that in all three age groups. The
steepest rise in incidence and least reduction in rate of rise was
seen in males aged 60 years and over.
While the number of cases with AJCC stage 3 or 4 at diagnosis
increased over the 25 years, they comprise only 255 (2%) of cases,
with the majority aged 60 years and over at diagnosis.
Table 3 shows incidence in each 5-year period by thickness,
o1.0, 1–1.99, 2–2.99, 3–3.99, and 4mm and over, and Figure 1
shows the incidence changes by age for the two groups under 1 and
4mm and over. Overall, 43% of cases were less than 1mm at
diagnosis, but the proportion in this good prognosis category has
increased significantly over time. In the first quinquennium
(1979–1983), 28% of melanomas in males and 27% in females
were under 1mm, while in the 1999–2003 quinquennium, 43% of
males and 50% of females had tumours under 1mm, a significant
rise in both (each: Po0.001).
In 1979–83, 32% of males and 24% of females had melanomas
4mm or thicker. By 1999–2003, the percentage 44mm had fallen
to 19% of males and 14% of females, a significant fall in both
(Po0.001). However, the actual incidence of melanomas 4mm or
thicker continues to increase in females but may have stabilised in
males when the most recent two quinquennia are compared.
Figure 1 shows that in the 4mm and thicker group, there are
significant increases in both sexes only in those aged 60 years and
over.
The greatest increase is seen in superficial spreading melanomas
in both sexes and all age groups (Table 4). This tumour type
comprises 59% of all cases and is the only type to have increased
significantly in all three age groups over the 25 years (Po0.001).
Lentigo maligna melanomas comprise 11% of all cases, and have
increased significantly in males aged 40–59 and 60 years and over,
and in females aged 60 years and over (Po0.001, for all). Nodular
melanomas comprise 20% of cases in males, and 16% in females,
and have increased significantly only in the over 60s of both
sexes (each: Po0.001). Acral melanomas comprise 10.3% of all
melanomas in males and 9.5% in females, and have increased
significantly in both sexes in the under 40 and 60 years and over
age groups (Po0.001 for all). (Data not shown)
The trunk continues to be the commonest primary site for males
and the lower limb for females (Table 5), but Figure 2 shows that
there has been a steep rise in head and neck lesions in those aged
60 years and over in both sexes (Po0.001). The greatest increase
Table 2 Number of cases (No.) and incidence in brackets adjusted to
EASR of invasive melanoma in Scotland 1979–2003 by quinquennia and
gender at ages under 40, 40–59, and 60 years and over at diagnosis
o40 40–59 60+
Age group (years) No. APC No. APC No. APC
Males
1979–1983 87 (1.22) 144 (5.07) 181 (9.38)
1984–1988 131 (1.73) 8.3 232 (8.19) 12.3 304 (14.96) 11.9
1989–1993 189 (2.50) 8.9 335 (11.44) 7.9 420 (20.26) 7.1
1994–1998 226 (3.00) 4.0 390 (12.64) 2.1 596 (27.53) 7.2
1999–2003 222 (3.09) 0.6 458 (13.72) 1.6 783 (34.17) 4.8
Females
1979–1983 160 (2.24) 279 (9.08) 352 (11.70)
1984–1988 273 (3.65) 10.8 405 (13.60) 10.0 570 (18.73) 12.0
1989–1993 333 (4.34) 3.8 440 (14.29) 1.0 726 (22.56) 4.1
1994–1998 386 (4.94) 2.8 572 (17.82) 4.9 868 (26.67) 3.6
1999–2003 432 (5.80) 3.5 629 (18.19) 0.4 978 (29.62) 2.2
Mean annual percentage change (APC) in italics. Year of birth for 349 (2.8%) subjects
not available.
Table 3 Melanoma in Scotland: numbers and incidence (brackets)
adjusted to EASR by quinquennia and tumour thickness
Thickness o1mm 1–1.99mm 2–2.99mm 3–3.99mm 4+mm
Males
1979–1983 125 (1.01) 64 (0.53) 53 (0.43) 55 (0.42) 142 (1.14)
1984–1988 231 (1.88) 147 (1.14) 80 (0.66) 63 (0.51) 178 (1.34)
1989–1993 383 (3.13) 192 (1.57) 102 (0.84) 80 (0.63) 186 (1.50)
1994–1998 484 (3.85) 237 (1.85) 127 (1.00) 82 (0.62) 245 (1.91)
1999–2003 607 (4.56) 307 (2.30) 139 (1.03) 90 (0.64) 260 (1.86)
Females
1979–1983 270 (1.81) 179 (1.18) 133 (0.83) 101 (0.58) 217 (1.17)
1984–1988 553 (3.89) 289 (2.03) 129 (0.91) 96 (0.60) 235 (1.27)
1989–1993 715 (4.94) 316 (2.18) 148 (0.98) 98 (0.58) 234 (1.22)
1994–1998 938 (6.61) 341 (2.28) 165 (0.97) 87 (0.48) 264 (1.35)
1999–2003 984 (6.58) 456 (2.95) 165 (1.00) 91 (0.49) 284 (2.42)
Thickness data missing for 48 subjects and not relevant for 255 who presented with
stage 3 or 4 disease.
Table 1 Distribution of 12450 cases by gender and quinquennium and
incidence in Scotland of melanoma age-standardised to the European
population (EASR)
Males n¼4810 Females n¼7640
Year Cases Incidence APC Cases Incidence APC
1979–1983 447 3.57 906 5.60
1984–1988 712 5.59 11.3 1312 8.75 11.2
1989–1993 954 7.75 7.7 1520 9.94 8.2
1994–1998 1217 9.53 4.5 1829 11.89 3.9
1999–2003 1480 10.93 2.9 2073 12.96 2.1
APC¼Mean annual percentage change in incidence by quinquennium.
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5 per year for
males and 0.83 to 2.58/10
5 per year for females.
Survival and mortality
Survival from melanoma within 5 years of diagnosis is shown in
Table 6 by gender and primary tumour thickness in 5-year periods.
There were 1066 patients who died of non-melanoma causes, and
these have been censored. Only 189 patients (2%) were lost to
follow-up, usually because they left the UK. As expected, survival
rates are highest in the thinnest tumour group and fall with each
1mm increase in tumour thickness. It is notable first that within
each thickness grouping, there has been a continuous and
significant improvement in survival (P for trend¼0.001 for males,
0.005 for females). Five-year survival rates for 1994–1998 range
from 93.6 and 95.8%, respectively, for males and females with
tumours under 1mm at diagnosis, to 52.4 and 48.35% for males
and females with tumours 4mm or thicker at diagnosis. In all
thickness groups up to 4mm, females have significantly superior
survival to males (Po0.001). Figure 3 shows mortality, which has
doubled in males from 1.1/10
5 to 2.4/10
5 per year and remained
constant at 1.510
 5 per year for females.
DISCUSSION
We show that between 1979 and 2003 the incidence of invasive
cutaneous melanoma in Scotland trebled in males and more than
doubled in females, the rise being most marked in those aged 60
years and over at diagnosis. In this age group, incidence in
Scotland is now greater in males than in females, a pattern not
reported before in the UK.
The general pattern worldwide is that in relatively low-incidence
countries female exceeds male incidence, but in higher-incidence
countries such as Australia, the incidence is either equal, or
there is a male preponderance (Coory et al, 2006). Thus, Scotland
appears to be moving toward the pattern of a high-incidence
country. A similar reversal has also been observed in New Zealand
(Martin and Robinson, 2004), but at a higher baseline level and
may suggest that females are more disposed to practice sensible
patterns of sun exposure with a consequently slower rate of
increase in older females than males. If this continues and is seen
in other countries, it adds to the evidence that recent sun exposure
contributes to melanoma risk as well as the established importance
of childhood and early adulthood exposure. This is of obvious
importance as it strengthens the case for sun protection messages
directed at older sections of the population.
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Figure 1 Changes in melanoma incidence 1979–2003 by age group for primary tumours o1.0 and 4mm and over at diagnosis. *Po0.001 when 1979–
1983 and 1999–2003 cohorts are compared.
Table 4 Melanoma in Scotland 1979–2003: numbers and incidence
(brackets) adjusted to EASR by quinquennia and histogenetic type
Type SSM LMM Nodular Acral
Males
1979–1983 200 (1.64) 54 (0.44) 117 (0.90) 62 (0.50)
1984–1988 364 (2.93) 80 (0.60) 169 (1.31) 73 (0.56)
1989–1993 515 (4.22) 115 (0.89) 189 (1.58) 101 (0.78)
1994–1998 677 (5.37) 129 (0.92) 243 (1.90) 112 (0.86)
1999–2003 851 (6.46) 187 (0.94) 228 (1.62) 148 (1.06)
Females
1979–1983 449 (3.08) 126 (0.62) 209 (1.18) 106 (0.62)
1984–1988 758 (5.54) 155 (1.77) 256 (1.59) 121 (0.70)
1989–1993 927 (6.61) 182 (0.91) 240 (1.44) 146 (0.85)
1994–1998 1198 (8.37) 168 (0.81) 257 (1.51) 156 (0.90)
1999–2003 1304 (8.82) 231 (1.12) 269 (1.49) 201 (1.09)
LMM¼lentigo maligna melanoma; SSM¼superficial spreading melanoma. 377
subjects (3%) not included as histogenetic type either not classifiable or belonging
to a rare group, for example, mucosal.
Table 5 Melanoma in Scotland: numbers and incidence (brackets)
adjusted to EASR by quinquennia and body site
Body site Head and neck Trunk Upper limbs Lower limbs
Males
1979–1983 118 (0.87) 144 (1.19) 37 (0.28) 82 (0.70)
1984–1988 176 (1.36) 280 (2.25) 72 (0.59) 113 (0.86)
1989–1993 247 (1.98) 375 (3.08) 97 (0.78) 150 (1.24)
1994–1998 306 (2.35) 464 (3.67) 155 (1.23) 180 (1.41)
1999–2003 385 (2.77) 559 (4.20) 224 (1.70) 199 (1.53)
Females
1979–1983 173 (0.83) 128 (0.86) 138 (0.83) 379 (2.62)
1984–1988 259 (1.42) 155 (1.17) 167 (1.13) 608 (4.38)
1989–1993 276 (1.41) 226 (1.69) 231 (1.62) 655 (4.55)
1994–1998 318 (1.68) 278 (2.06) 293 (1.97) 750 (5.13)
1999–2003 356 (1.76) 338 (2.42) 385 (2.58) 796 (5.34)
1178 (9%) evenly distributed between quinquennia and sex excluded as on less
common sites such as mucosal surfaces.
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the rate of incidence increase is levelling out, falling from 11.2%
per year for males and 11.3% per year for females when 1979–1983
figures are compared with 1984–1988 to 2.9% per year for males
and 2.1% per year for females when 1994–1998 figures are
compared with 1999–2003. This pattern is also seen in other
Northern and Western European countries, but contrasts with that
in Southern and Eastern Europe, where rates of incidence continue
to rise rapidly (de Vries et al, 2003). The reasons for these
Head and neck
0
2
4
6
8
10
12
14
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
1979–1983
1984–1988
1989–1993
1994–1998
1999–2003
Females Males
R
a
t
e
 
p
e
r
 
1
0
0
 
0
0
0
0
2
4
6
8
10
12
14
R
a
t
e
 
p
e
r
 
1
0
0
 
0
0
0
0
2
4
6
8
10
12
14
R
a
t
e
 
p
e
r
 
1
0
0
 
0
0
0
0
2
4
6
8
10
12
14
R
a
t
e
 
p
e
r
 
1
0
0
 
0
0
0
*
*
Trunk
Males Females
*
*
*
*
*
*
Upper limbs
Males Females
60+
EASR
0–39
40–59
0–39
40–59
0–39
40–59
0–39
40–59
60+
EASR
60+
EASR
60+
EASR
*
* *
*
Lower limbs
Males Females
* *
*
*
*
Figure 2 Changes in melanoma incidence 1979–2003 by body site and age group. *Po0.001 when 1979–83 and 1999–2003 cohorts are compared.
Table 6 Percentage 5-year melanoma-free survival for 8897 patients
diagnosed 1979–1998 by gender and tumour thickness
Thickness o1.0mm 1–1.99mm 2–2.99mm 3–3.99mm 4mm+
Males
1979–83 73.2 68.4 55.0 40.0 33.9
1984–88 82.7 78.3 56.5 45.1 30.8
1989–93 90.2 80.0 61.4 56.1 36.2
1994–98 93.6 87.9 71.3 65.3 52.4
Females
1979–83 86.0 84.9 62.9 55.7 37.6
1984–88 93.6 87.8 79.4 64.1 43.0
1989–93 93.5 94.9 77.4 66.2 44.8
1994–98 95.8 94.3 86.6 71.4 48.3 0
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Figure 3 Mortality from melanoma of the skin in Scotland 1980–2003.
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knowledge of the damaging effects of sun exposure in the paler
more vulnerable populations of Northern and Western Europe
resulting in an altered attitude and behaviour to sun exposure.
A continuing increase in melanoma incidence has been
predicted for both the UK and the Netherlands. Diffey (2004)
has suggested that any downturn in UK incidence attributable to
primary prevention activities may not be seen for 30 years, and de
Vries et al (2005) predicts an 80% increase in the Netherlands by
2015, both predictions taking account of the ageing population.
Our data do not contradict these predictions but the deceleration
in the rate of increase suggests that there will be smaller increases
than they forecasted.
Age groups
We show in Scotland a continuing incidence increase in both sexes
and all three age groups, greatest in both sexes at ages 60 years and
over. In contrast to Scandinavia (de Vries et al, 2003), we have no
evidence of a downward trend in incidence in younger females.
Many in Scotland’s ageing population currently retire relatively
early and spend a proportion of the winter months in warmer
climates, so incidence in this age group may increase still further
in the future, requiring the burden of melanoma care to be
increasingly directed toward older people.
Thickness
Our data show that the overall increase in incidence is significant
not only for melanomas less than 1mm at diagnosis, seen in all
three age groups, but also for thick tumours in those aged 60 years
and over. It has been suggested that much of the reported
worldwide increase in incidence reflects inappropriate pathological
interpretation of melanocytic lesions under 1mm thick as
melanoma rather than a benign melanocytic proliferation, which
include ‘lesions which lack the potential for metastasis’ (Burton
and Armstrong, 1998). The fact that in Scotland the increases affect
all thickness categories argues that the rise in incidence of
potentially fatal melanoma is real and not an artefact.
Histopathological subtype
The only subtype that has increased significantly in all age groups
over the 25 years is superficial spreading melanoma, and again
here the steepest increase is in males and females aged 60 years
and over at diagnosis. Over the 25-year period, nodular
melanomas have increased significantly only in males and females
aged over 60 years. This should be borne in mind in early detection
campaigns as nodular melanomas tend to be thicker than other
subtypes, and current public education concentrates mainly on the
less aggressive superficial spreading type (Demierre et al, 2005).
Lentigo maligna melanoma has increased in those aged 60 years
and over, with the steepest rise from 1994–1998 to 1999–2003.
This trend suggests an effect of total cumulative lifetime UV
exposure, which is believed to be of greater aetiological importance
for lentigo maligna melanoma than for other histological variants.
As in other Caucasian populations, we recorded a low incidence
of acral melanomas, but there were significant increases in those
aged under 40 and 60 years, and over in both sexes.
Body site
The steepest incidence increases were at age 60 years and over,
involving the head and neck and upper limb in both sexes, the
trunk in males, and the lower limb in females. If one assumes that
the head and neck in both sexes is a constantly UV-exposed site
whereas the trunk is an intermittently exposed site, then it would
appear that both the intermittent intense UV exposure associated
with sunny vacations, and chronic lifetime exposure are con-
tributing to the increase. Our observation that 50% of the head and
neck increase is due to lentigo maligna melanomas, and 50% to
superficial spreading and nodular lesions is further evidence that
this is the case.
Our site-related data suggest that while for all adults the male
trunk and female lower limb continue to merit stress in future
public awareness campaigns, head and neck lesions also require
emphasis for those aged 60 years and over.
Survival and mortality
Our data on 5-year survival show not only the well-recognised
significant survival advantage for patients with thinner melano-
mas, but also improvement in survival over 20 years within each
thickness category. Not all melanoma recurrences will be apparent
in the first 5 years of follow-up, but the proportion recurring later
is low. The reasons for the steadily improving survival after
controlling for thickness are not clear. Before 1998, neither sentinel
node biopsy nor adjuvant interferon therapy were standards of
care in Scotland, and therefore, even if ongoing trials on these
approaches eventually report a significant survival advantage,
they cannot explain the pattern observed for patients diagnosed
between 1979 and 1998. The female survival advantage within each
thickness category up to tumours 4mm and thicker has also been
reported from North America among 1829 patients (Scoggins et al,
2006) and its explanation merits further study.
Melanoma mortality over the 25-year period of observation has
more than doubled in males from 1.1 to 2.4/10
5 per year, with more
male than female deaths since 1985. In contrast, female mortality
has remained constant at 1.5/10
5 per year. These data indicate an
improvement in case fatality given the three-fold rise in incidence
in males, and 2.4-fold rise in females. This pattern of rapidly rising
incidence but more slowly rising mortality suggests that a
melanoma awareness campaign in Scotland in the mid 1980s had
some effect in encouraging earlier surgical excision of thinner
lesions (Doherty and Mackie, 1988). The static mortality in females
despite the male increase supports this view, as we observed a
predominance of females attending dedicated pigmented lesion
clinics during and after the campaigns (Mackie and Hole, 1992).
The only countries in Europe reported to show a continuing
increase in melanoma mortality are Scotland, France, Poland, and
Hungary (Bosetti et al, 2004) and the fact that only Scotland
showed a static mortality among females may be in part due to the
early detection public education in the 1980s.
The steady rise in melanoma incidence in Scotland over a
25-year period appears likely to continue, particularly in older
males. The failure of early detection activities to reach the older
male is also of concern in Australia (Janda et al, 2006), Canada
(Rivers and Gallagher 1995), and the US (Geller et al, 2002).
We consider that our data give a sound quantitative base for
future UK-based public education planned by CRUK and others.
The data indicate that primary prevention messages require to be
aimed at the whole population and early detection messages
should selectively target older males.
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